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A B S T R A C TProviding universal access to innovative, high-cost technologies leads to
tensions in today’s health care systems. The tension becomes particularly
evident in the context of scarce resources, where the risk of taking
contentious coverage decisions increases rapidly. To ensure economic
sustainability, the payers of health care think that the benefits from the
use of the new technologies need to be commensurate with the costs.
Therefore, many jurisdictions have programs of health technology assess-
ment, which often results in restrictions of access to care, either through
complete refusal to reimburse the technology or its restriction of use to
only a subset of the eligible patient population. However, manufacturers
feel that they should be adequately rewarded for their innovations and
require sufficient funds to invest in further research. Finally, patientssee front matter Copyright & 2013, International
r Inc.
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ondence to: Michael Drummond, Centre for Healthperceive these technologies to have added benefits, and so they are
concerned when they are denied access. If sustainable access to health
care is to be maintained in the future, approaches are needed to reconcile
these different perspectives. This article explores the approaches, in both
methods and policy, to help bring about this reconciliation. These include
rethinking the notion of social value (on the part of payers), aligning
manufacturers’ research more closely with societal objectives, and
increasing patient participation in health technology assessment.
Keywords: comparative effectiveness, health technology assessment,
patient participation, quality-adjusted life-year.
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Providing universal access to innovative, high-cost technologies
leads to tensions in today’s health care systems. Many of these
tensions arise from the fact that the main actors in the health care
sector have different perspectives on the value added by health
technologies. For example, the payers of health care feel that the
benefits from the use of the new technologies need to justify the
costs. Therefore, many jurisdictions have programs of health
technology assessment (HTA), which often results in restrictions
of access to care, either through complete refusal to reimburse the
technology or its restriction of use to only a subset of the eligible
patient population. The central notion of value in these assess-
ments is the cost per quality-adjusted life-year (QALY). (A similar
concept to the QALY, the disability-adjusted life-year is used in
assessments carried out in developing countries.)
However, manufacturers feel that they should be adequately
rewarded for their innovations and require sufficient funds to
invest in further research. They feel that the restrictions on the
use and price of health technologies resulting from HTAs limits
their sales potential and ultimately the profits from which future
research has to be funded. Manufacturers, however, sometimesset research priorities on the basis of the pursuit of a research
hypothesis, as opposed to developing new technologies that meet
unmet social need.
Finally, patients, and the clinical professionals who act as
their agents, perceive the value of health technologies in terms of
the benefits that these confer to the individual, irrespective of the
costs falling on society more broadly. The characterization of
these benefits may or may not be fully reflected in QALYs.
Therefore, patients are concerned when they are denied access
because of inadequate value for money, as expressed through the
incremental cost per QALY gained.
If sustainable access to health care is to be maintained in the
future, approaches are needed to reconcile these different per-
spectives. This article discusses three general strategies for
achieving this. In the next section, we discuss ways in which
payers might rethink the notion of value, including alternatives
to the QALY. Then, we discuss how health technology manufac-
turers might align their research and development more closely
with social objectives. Finally, we discuss how the participation of
patients and their representatives in HTA might be increased, so
that patients’ perceptions of the various treatment benefits can
be more closely aligned with those of payers.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
o conflicts of interest with regard to the content of this article.
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Growth of HTA
Faced with the rising costs of health care, governments and other
payers in many jurisdictions have introduced programs of HTA.
Increasingly, the assessments of the costs and benefits of new
treatments, in comparison with existing care, have become
‘‘hardwired’’ into the decision on whether to reimburse the new
technology.
The detailed methods of HTA vary from jurisdiction to
jurisdiction, but a common approach is to express the benefits
of treatments in terms of QALYs gained. (A similar concept to the
QALY, the disability-adjusted life-year has been adopted by the
World Health Organization and is widely used in assessments
carried out in developing countries) [1].
Comparisons are made between health technologies in terms
of their incremental cost per QALY gained as part of the
reimbursement decision. In some countries, such as the United
Kingdom, there is an explicit ‘‘threshold’’ of incremental cost per
QALY gained beyond which the new technology will not be
approved for reimbursement [2].Problems with QALYs
Because the QALY reflects the added years of life and the
improved quality of life resulting from treatment, it could be
argued that it is a reasonable measure of health gain. But is it a
reasonable measure of social value? In cost-benefit analysis, the
form of economic evaluation most closely aligned to classical
welfare economics, the benefits are measured by the sum of
individuals’ willingness to pay. This approach, however, has not
been extensively pursued in the health care field because of the
practical and emotional problems in assigning values to life
and death.
There are two main reasons why the QALY may not
adequately reflect social value. First, given the blunt nature of
some of the instruments used to assess changes in quality of life,
it is possible that these will not reflect all the aspects of
treatments that individuals care about. For example, QALYs are
unlikely to be sensitive enough to detect differences in the side-
effect profile of alternative treatments, or differences in conve-
nience resulting from different forms of administration (e.g., oral
medication vs. intravenous infusion).
Sometimes, health technology organizations compensate for
this in their decision-making procedures. For example, in an
assessment of treatments for metastatic breast cancer in the
United Kingdom, the National Institute for Health and Clinical
Excellence (NICE) eventually recommended two available taxanes
(taxotere and taxol) on the basis of evidence submitted by patient
groups that the drugs had different side-effect profiles. It there-
fore determined that the choice of taxane should be at the
discretion of the patient and her physician (J. Mossman, personal
communication, March 5, 2012).
Also, in its technology appraisal of quick-acting and long-
acting insulin analogues, NICE recommended that these more
costly medications could be used if the patient could not tolerate
frequent injections [3]. Both these decisions, however, resulted
from the discussions that took place in the Appraisal Committee,
rather than from the analysis of cost per QALY gained.
The second reason why the QALYs gained may not adequately
reflect social value relates to the way in which the QALYs are
normally aggregated in the technology appraisal. Each gain in
QALYs is treated as being equally valuable, no matter whether
the gain arises mainly from life extension or improved quality oflife. In addition, QALYs are valued the same no matter who
receives them.
While this approach could be viewed as egalitarian, it can also
be questioned. First, simple aggregation of QALYs requires that
the quality-of-life scale on which they are based has strict
interval properties. That is, a gain of 0.1 QALYs is valued the
same whether the patient’s health state (on a scale from 0 to 1) is
improved from 0.2 to 0.3 or from 0.8 to 0.9.
Some surveys suggest that improving the health of an indivi-
dual with a very serious health condition may be valued more
highly by the general public than improving the health of some-
one who is already reasonably healthy [4,5]. This notion is
reflected in the supplementary guidance given to the NICE
Appraisal Committee in the assessment of treatment for ‘‘end-
of-life’’ conditions. If the therapy is for a small patient population
with a life expectancy of less than 24 months and when the
therapy adds 3 months or more to life expectancy, the committee
can consider that the QALYs gained should be weighted greater
than unity if this means that the therapy could be approved given
NICE’s cost-effectiveness threshold [6].
Therefore, it is possible that for some health treatments and
technologies, appraisals based on health gain (expressed in
QALYs) may deviate from those based on social value. This is
illustrated in Figure 1 [7]. The technologies in cluster A have no
special characteristics to suggest that perceptions of social value
are highly positive or negative. Therefore, they may be reliably
appraised on the basis of their incremental cost per QALY.
Technologies in cluster B, however, while having a cost per QALY
lower than the threshold, have a perceived low social value.
Therefore, they may not be reimbursed, despite being ‘‘cost-
effective’’ by current criteria. Examples could be the surgical
removal of tattoos, or treatments for male impotence. However,
society may wish to reimburse technologies in cluster C, despite
the fact they are not cost-effective. Examples here could be end-
stage cancer treatments and drugs for rare diseases.
Alternatives to QALYs
Three alternatives to QALYs have been proposed. First, one could
leave the main clinical outcomes in their natural units and let the
trade-offs between them be made by the committee. This is the
approach suggested by the Institute for Quality and Efficiency
in Health Care in Germany [8]. To date, there is not enough
experience with this approach to provide an assessment of its
feasibility and usefulness.
The second approach would be to revert to providing esti-
mates of willingness to pay through contingent valuation. This
approach is now well established as a research methodology in
the health care field [9] but has not, so far, been widely accepted
by decision makers.
The third approach would be to conduct discrete choice
experiments (DCEs) to explore individuals’ valuations of the
various attributes of treatments. This approach has also estab-
lished itself as a research methodology [10] and is now attracting
the interest of decision makers. DCEs enable several attributes of
treatment to be valued relative to one another. These can include
not only clinical outcomes but also convenience and duration of
treatment.
Mu¨hlbacher et al. recently conducted a DCE for the (German)
Institute for Quality and Efficiency in Health Care (IQWiG) on
treatments for hepatitis C, considering both patients’ and clinical
experts’ opinions [11]. Levels of achievement for various attri-
butes of treatment were considered, including treatment efficacy,
treatment duration, frequency of injections, the probability of
adverse effects and their duration. The highest weight was given
to the main clinical attribute, probability of sustained virological
response, by both patients and experts, although other attributes
Fig. 1 – The relationship between social value and incremental cost per quality-adjusted life-year (QALY). Reprinted from Int J
Technol Assess Health Care, 23(1), Drummond MF, Wilson D, Kanavos P, Ubel P, Rovira J, Assessing the economic challenges
posed by orphan drugs, 36–42, 2007, with permission from Cambridge University Press.
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patients and clinical experts were also quite similar in this
example, although that may not be the case on all occasions.
In summary, there is a strong case for decision makers to be
rethinking the notion of value in health care. Activities could
include the exploration of differing weights for QALYs and
further experimentation with stated preference approaches, such
as DCEs, in real decision-making situations.Aligning Manufacturers’ Research with Social
Objectives
Research and Development in the Health Care Industries
Both the devices and pharmaceutical industries invest heavily in
research. In Europe, the medical device industry employs more
than 500,000 people and generates sales revenue of more than
h95 billion per year [12]. Of this h95 billion, 8% is ploughed back
into research and development each year, equivalent to around
h7.5 billion and to one new European patent every 38 minutes
[12]. The pharmaceutical industry spends nearly 17% of its sales
income on R&D, equivalent to US $35,000 million for the US
market and to h26,000 million in Europe. The average cost of
researching and developing a new chemical or biological entity is
constantly increasing and is estimated to be equivalent to h1059
million [13].
In times of resource constraints, when governments are
struggling to keep health care budgets under control, however,
it becomes crucial to discuss how much of the extensive invest-
ments in R&D made by the health care industries can be actually
recuperated by placing new products on the market. The gap
between the rates and pace of technological innovation and
economic growth is likely to increase in the future. Thus, if
access to health care is to be maintained in the future, manu-
facturers will have to align their research and development
strategies so as to contribute to the maximization of the socialobjective of providing the best possible quality and sustainable
care for the largest number of patients. This implies that
manufacturers need to rethink their clinical development process
and engage in early dialogue with payers and regulators, prior to
investing large amounts of resources in clinical studies.
Rethinking Clinical Development Strategy
In the past, much research has been about pursuing a clinical
hypothesis, rather than meeting an identifiable health need.
One implication of this is that certain disease areas are over-
studied and multiple technologies (e.g., molecules and devices)
developed. Often, these generate a small incremental benefit
(e.g., cancer treatment) while responding to the same patient
group’s needs. However, products in other disease areas may be
underdeveloped, with the potential of achieving bigger benefits in
absolute terms. Cost-of-illness analyses, which estimate the
economic burden of diseases together with their epidemiological
burden, would be useful in identifying areas of unmet health
needs where clinical research would have the potential to generate
high returns [14].
For instance, urinary tract infection, a major health care
concern that affects nearly 33% of healthy, sexually active women
whose quality of life has been estimated as worse as that
experienced by patients suffering from stroke and Alzheimers’
disease and exacerbated by its hidden and embarrassing nature
[15], had an economic burden of equivalent to 3% of Italian health
care expenditure in 2009, mostly paid for directly by patients as
out-of-pocket expenses, However, it is currently not associated
with a completely successful and effective treatment [16].
Second, the main emphasis in companies has been to design
clinical studies to meet the needs of the regulators (e.g., Food and
Drug Administration and European Medicines Agency). Most
clinical trials have been designed as placebo-controlled, non-
inferiority studies targeted at strictly defined patient populations,
aimed at reaching high internal validity. In both the United States
and Europe, however, there is a trend toward requiring studies
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that is, with a focus on external validity or generalizability.
In the United States, the American Reinvestment and Recov-
ery Act established a Federal Coordinating Council for Compara-
tive Effectiveness Research. This council defined comparative
effectiveness research as the ‘‘conduct and synthesis of research
comparing the benefits and harms of different interventions and
strategies to prevent, diagnose, treat and monitor health condi-
tions in ‘real-world’ settings’’ [17]. It noted that the purpose of
this research is to inform patients, providers, and decision
makers, responding to their expressed needs, about which inter-
ventions are most effective for which patients under specific
circumstances. To provide this information, comparative effec-
tiveness research necessitates the development, expansion, and
use of a variety of data sources and methods to assess relative
effectiveness through developing standards on internal validity,
generalizability, and timeliness.
In Europe, the EUnetHTA initiative was initiated in 2006 with a
work program focusing on a pan-European ‘‘core model’’ for HTA
in Europe, with initial reports on diagnostics, and medical and
surgical interventions. The 2011 EUnetHTA work program
includes research on pharmaceuticals and other technologies,
reflecting a recent focus in Europe on the relative effectiveness of
pharmaceuticals. The European Union High Level Pharmaceutical
Forum was developed in 2005 to bring the European Commission,
member states, representatives of the European Parliament, and
a wide range of stakeholders together to examine challenges
relating to providing information to patients on pharmaceuticals,
pricing, and reimbursement policy, and relative effectiveness
assessment. In its 2008 report [18], the forum adopted working
definitions of efficacy, relative efficacy, effectiveness, and relative
effectiveness. The report noted that the aim of a relative effec-
tiveness assessment is to compare health care interventions in
practice to classify them according to their practical additional
therapeutic value.
One implication of this trend for manufacturers’ clinical
development strategy would be to consider fewer placebo-
controlled trials, more superiority studies, longer duration of
trials, and measurement of end points of more interest to
payers/patients. The development of more ‘‘pragmatic’’ con-
trolled trial designs can serve these purposes. Pragmatic con-
trolled trials are intended to maintain the advantages of
randomization while examining outcomes in routine care. Prag-
matic controlled trials also have the advantage to better inform
economic analysis alongside clinical trials, which, if conducted
on ‘‘pure’’ experimental studies, would measure incremental
costs and outcomes under ‘‘ideal protocol-driven cost and effi-
cacy,’’ conditions often not confirmed in real-world settings.
Generating evidence about new pharmaceuticals and devices
is increasingly being seen as an activity that occurs throughout
the entire product life cycle, rather than prelaunch for a one-off
review at product launch. Drug regulatory authorities are explor-
ing both early access and provisional access schemes, in which
some studies about effectiveness and safety are conducted
postlaunch. Similarly, HTA/pricing and reimbursement bodies
are experimenting coverage with evidence development includ-
ing risk sharing that involves the collection of additional data
postlisting. At the same time, concerns about safety have led
to augmented postlaunch pharmacovigilance requirements. For
many of these efforts, prospective observational studies have
been the main vehicle for data collection.
Observational studies are particularly relevant for assessing
medical devices. Devices are intrinsically different from drugs
due to a number of important factors. These include the difficulty
in gathering clinical evidence from randomized controlled trials,
the effects of users’ learning curves, and different levels and
depth of organizational impact. This can pose challenges inundertaking assessments to inform decisions about the uptake
and diffusion of devices in clinical practice [19].
Engaging in Early Dialogue with Payers and Regulators
As previously mentioned, although regulatory agencies are
increasingly looking for evidence of comparative effectiveness,
there still is a gap between regulators’ and payers’ data needs.
While regulators are often satisfied with placebo-controlled trials,
or trials of short duration using intermediate or surrogate out-
comes, payers commonly ask for head-to-head trials, trials of
longer duration, and for evidence on final outcomes such as
survival rates and/or patients’ quality of life (e.g., QALYs).
Although manufacturers are traditionally focused on regulators’
requirements, being the ones necessary to get their technologies
licensed, they must nevertheless equally be attentive to payers’
needs if they want to maximize the chances of their technologies
being adopted in clinical practice. One possible way to reconcile
regulators’ and payers’ views is for manufacturers to engage in
early dialogue with payers before phase III trials.
In recent times, several pharmaceutical companies have
formed advisory boards, consisting of experts in HTA, pharmaco-
economics, and health care management, to gather advice on
how to better design phase III trials and/or how to better prepare
their value proposition dossiers once phase III trials have been
concluded. These efforts can undoubtedly provide manufacturers
with valuable advice on how to shape future market access
strategies; they would be further enhanced if manufactures could
also seek advice directly from payers and/or HTA agencies.
In a recent article, Backhouse et al. [20] report on a pioneering
effort by one technology developer to seek early dialogue with
seven pricing and reimbursement agencies in five countries on
their likely evidence requirements for a new oral treatment in
development for patients with chronic plaque psoriasis. The
questions concerned the most relevant design for the phase III
trial, namely, the target population, the relevant subgroups of
patients, the comparators, the outcomes of interest, the duration
of follow-up, and how nonresponders would have to be consid-
ered. The results of this pioneering effort confirmed that require-
ments of payers are different and often more demanding than
those deemed sufficient by regulators and, more importantly,
showed that, overall, there was more convergence than diver-
gence among the seven pricing and reimbursement agencies
than in the advice provided to the manufacturer. More evidence
is needed before concluding that this approach can actually make
manufacturers’ R&D investments more efficient while satisfying
at the same time both regulators and payers’ objectives. Perhaps
a tripartite dialogue between manufactures, payers, and regula-
tors would be even more useful [20]. Nevertheless, early dialogue
may represent a way forward to maximize the social objective of
providing the best possible quality and sustainable care for the
largest number of patients who could benefit from it.Increasing Patient Participation in HTA
As more innovative health technologies emerge on the scene, the
decision-making process becomes rather complex and inevitably
requires informed input by those who are mostly affected by the
adoption of these innovations. This becomes particularly evident
in the context of scarce resources where the risk of taking
contentious coverage decisions increases rapidly [21]. The origins
of patients’ involvement in health policy decisions can be traced
back to the customer-centered public management philosophy
and governance paradigm that has dominated public sector
decision making from the early 1990s [22]. Under this paradigm,
patients are not seen as passive recipients of information and of
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) S 7 – S 1 3 S11decisions taken by others, but assume a role of an active, well-
informed, and engaged interest group whose opinion is taken
into consideration [23].
As a result of this general trend, HTA community’s interest for
patient involvement has increased over the past decade. In 1998,
a special issue of the International Journal of Technology Assessment
in Healthcare was dedicated to the relationship between the
consumer and technology investigating, among other issues,
the patients’ perspective on the evaluation of health care and
the driving forces behind their increasing involvement [24]. In the
years to follow, numerous scientific publications explored the
issue of the general public’s and patients’ involvement and the
common emerging theme was that a greater effort must be made
to involve patients and citizens in determining priorities, in
evaluating the efficacy and cost-effectiveness of health care
interventions, and, even more importantly, in using the results
of these evaluations to make informed choices [25].
In 2005, the International Network of Agencies for HTA con-
ducted a survey among its members to assess the involvement of
consumers in HTA programs in different countries. The survey
revealed great differences between practices adopted by HTA
agencies. The most commonly reported approach to patient invol-
vement included consultations with patient representatives/orga-
nizations during the formulation of the assessment. Four agencies
(19%) reported providing training initiatives for patients, while
almost all agencies prepared ‘‘simple language’’ guidance to
increase accessibility [26]. The same year, Health Technology
Assessment International established a designated group for
patient and citizen involvement to promote ways in which patients’
needs, perspectives, and preferences could be incorporated into
HTAs via the generation of robust evidence and fair processes.
In contrast to this rising interest, the empirical evidence
generated over the past decade shows that the HTA community
itself is divided about the actual purpose of (why) and appropriate
methods (how) for involving patients in HTA [27,28]. Clarifying the
why and how of patients’ participation in HTA is deemed neces-
sary to explore more effective ways for incorporating patients’
input in assessing the value of innovative medical technologies.
Why Patient Participation in HTA?
There are at least three reasons that have been put forward to
support the idea that patients’ views must be taken into con-
sideration in HTA. The first is associated with the general
definition of HTA and evaluation of health technologies and
holds that a comprehensive assessment should take into account
not only clinical efficacy, cost-effectiveness, and equity issues but
also include patients’ views about satisfaction and acceptability
of health technologies. Patients have unique knowledge about
the technology that can and should inform an HTA [29]. The HTA
community is well aware of the fact that there is frequently a gap
between the perspectives and values of HTA practitioners and
those of patients that could lead to unsatisfactory decisions. It
has been repeatedly argued that scientific evidence produced by
randomized controlled trials do not adequately reflect values of
patients, their needs and desires, and cannot be used as the sole
input to HTA. This reveals a need for broadening the evidence
base on which the decisions are made by taking into account
patients’ input [30]. The rise of so-called personalized-medicine
further reinforces the need to involve patients in HTA.
The second reason for promoting greater patient involvement
in HTA stems from the general epidemiological trend taking place
in developed countries: a rather dramatic shift of acute to chronic
diseases. With chronic forms of disease and disability, patients
and their families play a more active part in health care and
patients’ life style and behavior can dramatically influence the
long-term prognoses of chronic conditions [24,30].The third reason for greater patient involvement in HTA is
concerned more with the decision-making process: involving
patients increases transparency and openness in the public
policy. Thus, patients’ involvement should emphasize a deliberative
process through which normative assumptions underlying HTA are
made more explicit [23]. As part of this, transparency about the
influence of the patient perspective is essential. It is argued that,
otherwise, HTA will have little chance of achieving its goals and
it would also be hard to sustain public support for funding HTA
if the public remains ignorant of its importance and relevance
to them.
How to Effectively Ensure Patients’ Involvement in HTA?
Although most agree that the reasons highlighted in the previous
section are strong enough to justify the effort needed to involve
patients in HTA, the evidence suggests that there are several
barriers to effectively doing so in practice [28]. The main obsta-
cles stem from the following issues: 1) robustness of evidence on
patients’ perceptions, 2) clarity on the type of patients’ input
needed, 3) the knowledge base required for patients to make an
effective input, and 4) lack of awareness of patients and their
associations on potential involvement. Understanding and
overcoming these barriers can greatly help identify strategies
for how to effectively implement patients’ participation in the
HTA process.
Identification and synthesis of information from patients
raises a series of methodological questions and challenges [29].
The widespread barrier for patient participation in HTA is a belief
that evidence collected on patients’ views is anecdotal and
biased. Patient experiential information frequently requires dif-
ferent methodological approaches (e.g., focus groups and inter-
views) mainly qualitative in nature. This is in contrast with HTA
being mainly influenced by the quantitative and positivism
paradigm that emphasizes systematic reviews and the hierarchy
of quality of evidence. Currently, there is little guidance on how
to effectively collect the evidence, given the resource and time
constraints faced by HTA bodies. To respond to this critique, it
has been suggested that methods should be developed for
gathering data on patients’ views. For example, in addition to
more qualitative approaches, standardized tools could be
employed, such as validated patient-report outcome measures.
In the absence of relevant primary data, systematic reviews of
existing secondary and primary studies on patients’ perspectives
should be conducted. In this respect, particular attention should
be given to developing tools to assess and synthesize qualitative
studies [29].
The enhanced methods should also foster greater clarity on
what type of information should be collected from patients. For
example, patient input may include the following: preferences for
health states, information about costs borne by the family in
seeking/receiving care, views on the experience of care, involve-
ment in the care process, and the convenience of different forms
of treatment (e.g., oral medication vs. intravenous infusion,
different dosing schedules).
To ensure an effective and relevant input into the HTA
process, patients should have some knowledge about the basic
concepts and terminology used in the assessment. In this
respect, training opportunities for patients and their representa-
tives should be promoted by both HTA bodies and associations
themselves. For example, a patient decision aid has been recently
developed for breast cancer patients on the basis of systematic
literature review and primary data collected through qualitative
study. The evidence collected suggests that patient decision aid
allowed patients to access information, gain additional knowledge
of their illness, and make shared treatment decisions and gave
health care professionals a deeper insight into patient experiences
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areas to allow for more informed and effective input from those
experiencing the technology under assessment.
Finally, lack of awareness on the part of patients of the policy
process and of opportunities for their involvement is frequently
cited among the barriers to effectively include patients in HTA
[28,32]. It is suggested that health care organizations and HTA
bodies should engage in outreach activities to inform patients and
their representatives of the possibilities to participate in HTA.
The above are just a few suggestions on how patients’
participation in the HTA process should be enhanced to accom-
plish meaningful and valuable input. It must be mentioned,
however, that research offering insights into the effectiveness
of different approaches is currently scarce [33].
In addition to identifying appropriate strategies for encoura-
ging patients’ involvement, it is essential to clarify the phases of
the HTA process in which patients’ input should be encouraged.
Most commentators argue that patient involvement should be
increased in all phases of HTA. This can be achieved by giving an
opportunity to patients to become effective members of expert
committees involved in 1) scoping of technology assessments,
2) commenting on draft reports and providing views on proposed
recommendations, and 3) appealing the reimbursement/coverage
decisions. However, a recent review shows that the extent to
which patients are currently being involved in these three types
of activities varies greatly across countries [25].Discussion and Conclusions
In this article we have argued that to achieve universal access to
innovative and costly technologies, the different perspectives of
payers, manufacturers, and patients need to be reconciled.
Although we have identified a number of possible initiatives, it
is still not clear how such reconciliation would be achieved. It is
important, however, to note that several initiatives are already
taking place, in that manufacturers are engaging in more dialo-
gue with payers and regulators, and some HTA programs are
encouraging patient participation.
Indeed, the cornerstone to more progress is to develop and
maintain an effective and efficient program for the comparative
assessment of health technologies in a given jurisdiction.
Drummond et al. [34] identified 15 key principles for the conduct
of HTA for informing resource allocation decisions. These cov-
ered the structure of the HTA program (e.g., its level of indepen-
dence, the methods for HTA (e.g., the incorporation of a broad
societal perspective and the consideration of all types of clinical
evidence), the processes followed (e.g., the involvement of stake-
holders including patients), and the link with the decision-making
process (e.g., the incorporation of different sets of values and the
communication of findings to different constituencies).
A study of 14 HTA organizations showed that there was
considerable variation in the acceptance and adoption of these
principles across the various agencies [35]. Although in a later
article, Drummond et al. [36] point to the challenges in making
direct comparisons between particular HTA agencies, this
research suggests that there is room for improvement in current
HTA practice.
It can be argued that there are other interest groups, such as
health care providers and general public, whose input should be
considered as well. While we recognize their importance, we argue
that the three perspectives chosen (patients, payers, and manu-
facturers) are the most important. In a public health care system,
citizens are represented in principle by their democratically elected
government, a third-party payer. Providers, however, are influenced
by, and greatly dependent on, the coverage and reimbursement
decisions made by the payer. Thus, while the three interest groupswe focused on in our analysis are not the only players in the health
care arena, we believe that reconciling their values is essential for
ensuring access to innovation in health care.
Although all jurisdictions would benefit from an effective and
efficient HTA (or comparative effectiveness) program, other
initiatives may depend on the current focus of the health care
system in the jurisdiction concerned. In many European coun-
tries, the organization of health care could be said to be
‘‘population focused.’’ That is, health care is financed through
general taxation or social insurance and decisions about the
availability of treatments are made on a collective basis. In these
systems, there has been a growing interest in making reimburse-
ment decisions on the basis of HTAs and, more recently, in value-
based pricing [37]. These initiatives are likely to give manufac-
turers an incentive to more closely align their R&D with social
objectives. As mentioned above, however, it is important to
ensure, through adequate stakeholder involvement, that the
values incorporated in processes such as HTA and value-based
pricing do adequately encompass social values.
Other health care systems, in the United States and several
middle-income countries in Asia and Latin America, could be said to
be more ‘‘patient focused.’’ That is, patients play a direct role in
determining the type of coverage they have and also make pay-
ments at the point of receiving care. In these jurisdictions, perhaps
the main role of HTA and related efforts is to make patients more
aware of the relative benefits of different health technologies so that
they can make more informed choices. This can be reinforced by
employing ‘‘value-based’’ insurance designs [38] and value-based
formularies [39]. Here, the role of the payer is not to impose a
particular set of values, but to be clear on which technologies should
attract higher or lower co-payments and to facilitate more informed
consumer choice, thereby increasing the alignment of patients’ and
manufacturers’ values though a quasi-market.
Although different health care systems may require slightly
different approaches, there are also linkages. For instance,
Drummond and Towse [40] recently questioned whether, in the
context of value-based pricing, the role of patient co-payments
for pharmaceuticals should be reconsidered, with a view to
encouraging more efficiency.
The points raised in this article also suggest an agenda for
future research. This includes the testing, in a decision-making
context, of some of the alternatives to QALYs. In addition, further
research is required into the use of observational studies in the
assessment of health technologies. Finally, some of the processes
discussed above, such as the methods of increasing patient
involvement in HTA and early dialogue between manufacturers,
regulators, and payers, require more research so that they can be
made as cost-effective as possible.
A reconciliation of payers’, manufacturers’, and patients’
perspectives on the value of health technologies presents several
challenges, but it is not unattainable.Acknowledgments
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